Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.1K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.1K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.1K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.1K
Development of Immunocompetence01:22

Development of Immunocompetence

1.1K
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1.1K
Transcytosis of IgG01:15

Transcytosis of IgG

4.4K
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
4.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

672
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
672
Cross-reactivity00:42

Cross-reactivity

33.6K
Overview
33.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

[Relevance of the ACT score in severe asthma with obesity: A pilot study].

Revue des maladies respiratoires·2026
Same author

[Emergency room visits for asthma and the reported outcomes: The PASS survey by the CRISALIS network].

Revue des maladies respiratoires·2025
Same author

[The role of the cardiopulmonary exercise test and pulmonary rehabilitation in long COVID-19].

Revue des maladies respiratoires·2023
Same author

[An action plan for everyone !]

Revue des maladies respiratoires·2023
Same author

[Global Lung Initiative reference values are recommended for pulmonary function testing in France: A statement from the Lung Function Group of the French-Speaking Pulmonology Society].

Revue des maladies respiratoires·2023
Same author

[A rare and atypical form of tularemia in a context of immunodepression].

Revue des maladies respiratoires·2023

Related Experiment Video

Updated: Mar 7, 2026

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

14.6K

[Omalizumab: Beyond anti-IgE properties].

J-M Perotin1, C Barnig2

  • 1Service des maladies respiratoires, Inserm UMRS 903, centre hospitalier universitaire, 45, rue Cognacq-Jay, 51100 Reims, France.

Revue Des Maladies Respiratoires
|February 13, 2017
PubMed
Summary

Omalizumab, an anti-immunoglobulin E therapy, shows anti-inflammatory effects beyond IgE by reducing immune cells and cytokines. This may explain its efficacy in non-allergic conditions and guide biomarker discovery for severe asthma.

Keywords:
Asthme sévèreBronchial remodelingEosinophilsImmunoglobulin EImmunoglobulines EOmalizumabRemodelage bronchiqueSevere asthmaÉosinophiles

More Related Videos

Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein
08:04

Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein

Published on: December 20, 2017

7.4K
Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.6K

Related Experiment Videos

Last Updated: Mar 7, 2026

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

14.6K
Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein
08:04

Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein

Published on: December 20, 2017

7.4K
Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.6K

Area of Science:

  • Immunology
  • Allergology
  • Pharmacology

Background:

  • Omalizumab is a treatment for severe allergic asthma targeting immunoglobulin E (IgE).
  • Emerging evidence suggests omalizumab possesses additional mechanisms of action beyond its anti-IgE properties.
  • These alternative pathways may contribute to its therapeutic effects.

Purpose of the Study:

  • To explore the multifaceted mechanisms of action of omalizumab.
  • To understand how omalizumab impacts immune cells and inflammatory pathways.
  • To investigate the potential of these mechanisms in non-allergic conditions.

Main Methods:

  • Review of recent studies on omalizumab's cellular and molecular effects.
  • Analysis of omalizumab's impact on immune cell populations (dendritic cells, T/B lymphocytes, eosinophils).
  • Assessment of cytokine level modulation and effects on bronchial remodeling.

Main Results:

  • Omalizumab treatment decreases dendritic cells, T/B lymphocytes, and eosinophils.
  • It reduces cytokines involved in eosinophil and mast cell activation and survival.
  • Omalizumab modulates bronchial remodeling by decreasing extracellular matrix production and smooth muscle cell proliferation.

Conclusions:

  • Omalizumab's broader anti-inflammatory actions, including immune cell modulation and anti-remodeling effects, contribute to its efficacy.
  • These mechanisms may explain its effectiveness in non-allergic conditions like asthma, urticaria, and nasal polyposis.
  • Identifying predictive biomarkers of omalizumab efficacy is crucial for severe asthma phenotyping.